Enhanc3D Genomics
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
* | £10.0m | Series A | |
Total Funding | AUD20.4m |
Related Content
Recent News about Enhanc3D Genomics
EditEnhanc3D Genomics is a functional genomics company focused on exploring the 3D organization of DNA to understand its impact on health and disease. The company operates in the biotechnology sector, serving pharmaceutical companies, research institutions, and healthcare providers. Its core product, the GenLink3D platform, integrates proprietary molecular biology technologies with machine learning to analyze genetic variations in non-coding regions of the genome. This platform helps identify how these variations influence disease progression, thereby aiding in the development of targeted therapies and precision medicine. Enhanc3D Genomics generates revenue through licensing its technology, offering genomic analysis services, and collaborating on research projects. The company is backed by investors such as Bioqube Ventures, Start Codon, BGF, Parkwalk, and private investors.
Keywords: functional genomics, 3D DNA organization, precision medicine, therapeutic development, GenLink3D, molecular biology, machine learning, genetic variations, non-coding regions, biotechnology.